Letrozole for the treatment of pretreated advanced breast cancer patients: Preliminary report

A. Casali, F. M. Sega, M. Casali, T. Giuntini, G. C. Antonini Cappellini, E. Terzoli

Research output: Contribution to journalArticlepeer-review

Abstract

Twenty patients (pts) with metastatic breast cancer with disease progression, previously treated with chemotherapy and tamoxifen, were administered oral letrozole (2.5 mg/day) therapy. Fifteen of the patients were postmenopausal and 5 were premenopausal. Ten were estrogen receptor (ER)-positive, 7 were unknown and 3 were ER-negative. All the patients were assessed after 6 months (mo) of chemotherapy. Nine pts (45%) presented a partial response (PR), five (25%) had a stable disease (SD) and six (30%) had a progressive disease (PD). In the pts with PD, six out of 15 (33%) obtained a PR while undergoing tamoxifen therapy. The treatment caused no significant toxicity.

Original languageEnglish
Pages (from-to)17-19
Number of pages3
JournalJournal of Experimental and Clinical Cancer Research
Volume19
Issue number1
Publication statusPublished - Mar 2000

Keywords

  • Aromatase
  • Estrogen receptors
  • Letrozole
  • Menopause

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Letrozole for the treatment of pretreated advanced breast cancer patients: Preliminary report'. Together they form a unique fingerprint.

Cite this